Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31273984 | 1.00 | MEN1 (0.38) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL1830869 | 1.00 | MEN1 (0.38) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL15948910 | 0.85 | CHRM2 (0.46) | MEN1KMT2ALMNACA2CHRM2 | |
| SCHEMBL15301330 | 0.76 | MEN1 (0.37) | MEN1KMT2ALMNACHRM2CHRM4 | |
| SCHEMBL3898973 | 0.75 | ALDH1A1 (0.34) | MEN1KMT2ALMNACA2ALDH1A1 | |
| SCHEMBL10813862 | 0.74 | MEN1 (0.36) | MEN1KMT2ALMNA | |
| SCHEMBL12021714 | 0.73 | SLC6A2 (0.35) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10368095 | 0.72 | MEN1 (0.33) | MEN1KMT2ALMNACA2 | |
| SCHEMBL4510179 | 0.71 | JAK2 (0.39) | MEN1KMT2ACHRM2CHRM4CHRM5 | |
| SCHEMBL10041484 | 0.71 | CA1 (0.43) | MEN1KMT2ALMNACA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4463457-B1 | PYRROLO[1,2-B]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LTD (IN) | 2026-02-04 | — | — | EP | disclosed |
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-04-15 | — | — | US | disclosed |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | SUVEN LIFE SCIENCES LIMITED (IN) | 2025-01-16 | — | — | US | disclosed |
| US-8163920-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163920-B2 | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20100311979-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311979-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12275746-B2 | Pyrrolo[1,2-b]-2-pyridazinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1B | MEN1 1702/4885KMT2A 3971/4885LMNA 4071/4885 |
| US-20250019386-A1 | PYRROLO[1,2-b]-2-PYRIDAZINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1B | MEN1 1702/4885KMT2A 3971/4885LMNA 4071/4885 |
| US-20100311979-A1 | QUINOLINONE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR1A | MEN1 1587/4885KMT2A 1511/4885LMNA 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.